• 

  Alzheimer’s Association All In On Not-Yet-Approved Aducanumab
• 

  Phil’s Journal: A Lesson on Living With Alzheimer’s, Courtesy of My Dog
• 

  ‘The Problem of Alzheimer’s’ Makes Us Mad—In a Good Way
• 

  FDA Delays Aducanumab Decision
• 

  What Happens If Aducanumab Wins FDA Approval? It’s Complicated
• 

  Experimental Alzheimer’s Drug Donanemab Looks Promising in Phase 2 Trial
• 

  Phil’s Journal: Reflections on Alzheimer’s Drug Aducanumab’s Latest Snag
• 

  Aducanumab Setback? FDA Advisory Committee Meeting Presents Unexpected Snag
• 

  FDA Moves Forward on Aducanumab
• 

  Alzheimer’s Drug Trials Have Had a 99% Failure Rate. The Good News: There Are Currently More Than 100 in the Pipeline
• 

  Phil’s Journal: Being Part of Scientific History, or, a New Phase of the Biogen Trial
• 

  Phil’s Journal: Trials and Tribulations, or, My Latest Experience in Biogen Research
• 

  Phil’s Journal: Waiting While Approval for Biogen’s Alzheimer’s Drug is Delayed, Yet Again
• 

  Phil’s Journal: Pandemic Disrupts Alzheimer’s Clinical Trials. Including Mine
• 

  Phil’s Journal: My Good Friend Is the First to Receive Biogen’s Alzheimer’s Drug in New Trial

Previous345Next